U.S. Markets close in 3 hrs 31 mins
  • S&P 500

    4,395.64
    +41.45 (+0.95%)
     
  • Dow 30

    34,258.32
    +338.48 (+1.00%)
     
  • Nasdaq

    14,896.85
    +150.45 (+1.02%)
     
  • Russell 2000

    2,218.56
    +32.38 (+1.48%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    42,164.79
    -1,597.27 (-3.65%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Mylan Topped Large-Caps with New Launches, Share Repurchase Plan

IBB Leads Biotech ETFs in Weekly Update, Mylan Tops Large-Caps

(Continued from Prior Part)

Mylan contributed to IBB’s large-cap performance

The large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) outperformed the large-cap stocks of other biotech ETFs for the week ended November 20, 2015. IBB’s large-cap stocks were the best performers with a return of 3%. The iShares US Healthcare Providers ETF (IHF) was the worst performer with a return of 1.2% for the same period.

The above graph reflects the returns of large-cap stocks of various biotech ETFs compared to the SPDR S&P 500 ETF (SPY) for the week ended November 20. SPY outperformed other biotech ETFs with a return of 3.4% for the same period.

Mylan topped the large-caps with new launches and share repurchase plan

Mylan (MYL) stock rose 6.4% for the week ended November 20, 2015. It went up on a couple of new drug launches and a share repurchase plan. According to the press release, MYL has announced “the U.S. launch of Almotriptan Tablets USP, 6.25 mg and 12.5 mg, the generic version of Janssen Pharmaceutical’s AXERT®. Mylan received final approval from the U.S. Food and Drug Administration ([or] FDA) for its Abbreviated New Drug Application ([or] ANDA) for this product, which is used for the acute treatment of migraine attacks in adult patients with a history of migraine with or without aura.”

MYL also announced “the U.S. launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity amphetamine product), 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg, which is the generic version of Teva’s Adderall® Tablets…indicated for the treatment of attention deficit hyperactivity disorder ([or] ADHD).”

On November 16, 2015, Mylan announced that its board of directors has authorized the repurchase of ordinary shares in an amount up to $1 billion. The stock closed at $51.87 and was trading above the 50-day and 100-day moving averages. MYL has a weight of about 4.0% in IBB.

The other large-cap stocks that performed well are Vertex Pharmaceuticals (VRTX), Illumina (ILMN), and Regeneron Pharmaceuticals (REGN), with returns of 6.1%, 5.3%, and 5.6%, respectively.

Continue to Next Part

Browse this series on Market Realist: